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Abstract
Aim: The aim of the present study was to review the papers in the published literature and to compare the clinical trial method-
ology used in these studies to evaluate the products for Dentine Hypersensitivity (DH) based on the previously recommended 
guidelines of Holland, et al. (1997).
Material and Methods: A systematic search was conducted on PubMed and Embase for double blind randomized placebo-con-
trolled clinical studies conducted over ≥6 weeks assessing the efficacy of OTC products for the treatment of DH in otherwise 
healthy adult subjects with reported and diagnosed DH.
Results: A total of 35 studies were included in this review from an initial search of 882 titles. All the included studies complied 
with the guidelines in terms of study design, duration, subject selection, adequate control(s) and subject instructions. 91% of 
studies used a sample size of ≥ 25 per arm. Most studies (91%) complied with the minimum required number of teeth to be test 
ed except in two studies. All the studies used an objective assessment however only two studies (22.8%) included a subjective 
evaluation to an everyday stimulus when evaluating DH. Only two studies included assessment of the impact of DH treatment 
on the participants’ Quality of Life (QoL). Most studies did not include a recommended specific run in/wash period (10 studies 
[28.5%]) or a follow up period following the cessation of the study (2 studies [5.7%]). All studies reported the reduction of DH 
as a percentage reduction from baseline values. None of the studies reported a total relief of pain irrespective of the in- terven-
tion(s) evaluated although there were mean reductions in both test and control groups.
Conclusions: All of the included studies reported a significant statistical reduction of pain in both the test and control groups, 
although none of the studies reported the complete absence of the pain response following any of the interventions at the end of 
the studies. Overall, most studies complied with the recommendations from the Holland, et al. guidelines however, there is still 
a need to include both a run in/wash out and follow up periods in future studies. Furthermore, it may be recommended to include 
a subjective evaluation of the treatment outcome to overall sensitivity from day to day activities as well as the effect on the QoL 
(person-centered approach) in future studies. None of the included studies reported the complete absence of the pain response 
following any of the interventions at the end of the studies.
Introduction
Dentine Hypersensitivity [DH] has previously been defined 
as ‘pain derived from exposed dentin in response to chemical, 
thermal tactile or osmotic stimuli which cannot be explained as 
arising from any other dental defect or disease [1-2]. It is evident 
from the published literature that DH is a common problem in 
the adult population although its true impact on those individuals 
suffering with the condition varies [3] particularly in relation to 
their quality of life [4-5]. The pain associated with DH is episodic 
(transient) in nature and will generally ease once the stimulus 
has been removed. The prevalence rates vary depending on how 
the data was collected or where the studies took place (e.g., 
questionnaire, surveys or clinical examination; general practice, 
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university hospital or consumer based) and these may range form 
1-74% [6]. DH tends to be underestimated by clinicians due to 
the difficulty in diagnosis [7]. The condition generally involves 
the facial surfaces of teeth near the cervical aspect and is very 
common in premolars and canines followed by the upper first 
molar with the incisors being the least sensitive teeth [7-10]. To 
treat the condition a number of Over the Counter (OTC) and In-
office (Professionally applied) products have been developed for 
patients/consumers and are evaluated in an in vitro environment 
prior to clinical evaluation to determine their safety as well as their 
effectiveness in successfully treating the condition. It is important, 
however, to assess these products in an in vivo environment to 
determine both safety and efficacy of the products and as such 
clinical trial design is an important aspect in the evaluation of 
the efficacy of these products and describes the manner in which 
patients will be studied in terms of selection, treatment and 
assessment [11]. There are four types of clinical trial designs, 1) 
randomized (parallel arm), 2) pre-treatment period, 3) crossover, 
and 4) split-mouth. When evaluating products for the treatment 
of DH, a double blind randomized parallel group has been 
recommended in which all subjects are allocated to either a test 
or control groups, and the difference in outcome across the group 
will determine any significant efficacy of the test group [12]. There 
are several problems associated with studies for testing products 
of DH such as placebo and no-placebo effects, the objective 
methodology used to evaluate DH as well as the highly subjective 
of the pain response [13]. In order to reduce these effects Holland, 
et al. [12] made a number of recommendations or guidelines such 
as the experimental design, sample size, subject selection, teeth 
and sites to be tested, test stimuli, controls, wash-in/wash-out 
period, subjects, instruction duration, assessment, outcome, and 
follow up when conducting clinical trials for evaluating products 
in the treatment of DH. It was apparent, however from reading the 
published literature that some studies do not necessarily conform 
to these guidelines when evaluating these products. 
Aim
The aim of the present study, therefore was to review the 
papers in the available literature and to compare the clinical trial 
methodology used to evaluate the products for DH based on the 
inclusion criteria of the guidelines previously recommended by 
Holland, et al. [12].
1) The objectives of the study are as follows: 
2) Identify clinical trials that evaluate OTC products for DH
3) Describe the methodological quality of these studies and their 
main features and characteristics. Compare the methodology 
of the included studies with the recommendations of Holland 
et al. [12] in terms of experimental design, sample size, subject 
selection, teeth to be included, test stimuli, controls, wash-in/
wash-out period, subject instruction, duration, assessment, 
outcome, follow up, number of studies, products used in the 
over the counter (OTC) interventions.
4) Present any pertinent implications for future trial design for 
DH studies.
Materials and Methods
Method of the review
This systematic review was conducted in agreement with the 
recommendation of the principles of the PRISMA statement [14]. 
The focus question was: Do clinical trials evaluating the efficacy of 
products for treatment of DH follow the guidelines recommended 
by Holland, et al. [12]?.
Methodology
Inclusion criteria
Types of studies 
The review will include all studies in English, full text, 
double blinded randomized controlled clinical trials conducted in 
human subjects to test the efficacy of products for DH. Duration of 
the selected studies will be at least 6-8 weeks in duration. 
Types of participants
Healthy dentate adults (at least 18 years old) with a reported 
and established history of DH. 
Types of interventions
Participants should be randomly allocated to one of the following:
1) Test: agent or product (the formula and concentration should 
be stated by authors).
2) Control: (should be the same as the test but without the active 
agent.
Types of outcome measures
Included studies should assess the change in response to the 
test procedures including tactile, thermal and air blast stimuli or a 
patient subjective assessment of pain during every-day activities.
Exclusion criteria
Types of studies 
Single case reports, in vitro, in situ or review articles were 
excluded.
Types of participants 
Studies were excluded if the subjects were not described 
or if the subjects were taking any analgesic drugs due to medical 
problems or if the subjects received any periodontal therapy during 
the period of trial, and whether the sensitivity was due to caries, 
bleaching, or endodontic reasons. 
Types of interventions
Studies were excluded if the test product contained fluoride 
and the test did not.
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Types of outcome measures
Exclude any unknown methodology.
Other relevant criteria for inclusion 
1) Investigator calibration on assessment of DH prior to the 
commencement of the study
2) Randomization of the participants into different groups was 
clearly described such as the concealment of participants and 
group allocation to both investigators and participants.
Search strategy
The search strategy included the use of the electronic data 
bases PUBMED and Embase up to 21.12.2016.  The searching 
Keywords in PUBMED ((((((((((dentifrice) OR dentifrices)) 
OR (((toothpaste) OR toothpastes) OR tooth paste)) OR 
((desensitizing) AND products))) AND ((dentine) OR dentin)) 
AND ((hypersensitivity) OR sensitivity)))) NOT (((((laser) OR 
endodontic) OR bleach) OR whitening) OR caries). The reference 
list of the included studies and the relevant reviews were manually 
searched.  Only articles published in the English Language were 
selected.
Study Selection
Studies were selected in a two-stage screening process and 
performed by two of the three independent reviewers (AK/DC/
DG). Disagreement about the inclusion or exclusion of a study was 
resolved by consensus. The first stage screening of the titles and 
abstracts was performed to eliminate irrelevant articles and those 
that did not fit the inclusion criteria established by this review. 
At the second stage following the reading of the full text of each 
article, the study eligibility was verified independently by two of 
the three reviewers and data extraction and quality assessment 
was performed for the included studies based on randomization, 
allocation concealment, blinding, and description for dropout. Any 
disagreement was be resolved after discussion between AK and 
DG.
Risk of Bias of Included Studies
This was assessed according to the criteria of concealment 
of treatment allocation described in the Cochrane handbook for 
systematic reviews of interventions [15]. Allocation concealment 
for each study was rated as a) Adequately concealed, b) 
Concealment is unclear, c) Inadequately concealed. Blinding was 
also assessed as a) Double blinded, b) Single blinded, c) Blinding 
is mentioned but is suspicious or uncertain [16].
Statistical Analysis
No statistical or meta-analysis analysis was undertaken in the 
present study, descriptive summaries of the studies are presented 
in the results section.
Results
Overall Description of the Included and Excluded Studies
The flow chart representing the study selection and inclusion 
is shown in Figure 1. The initial search resulted in 878 articles; 
an additional four articles were identified by manual searching by 
hand. Following the first stage screening of titles and abstracts, 
121 articles qualified for full-text screening. Following the full 
text reading, 35 articles met the defined criteria, 86 articles were 
excluded as follows: 1) in office procedures (27) 2) Insufficient 
duration of study (20) 3) Inadequate controls, randomization, 
blinding (18) 4) Review papers (6), 5) In vitro studies (8), 6) In 
situ studies (2), 7) Editorial (1), 8) Publications not in the English 
language (1 in vitro and 2 in-office) [3], 9) Adjunctive use of OTC 
products (1). With regards to the type of product that was under 
investigation, the studies can be divided into four categories, OTC 
products, OTC products combined with another over the counter, 
in office products, and in office products combined with OTC 
products. For purpose of this review only studies which test OTC 
without any adjunctive will be considered.
Figure 1: The flow diagram of the study selection process.
Excluded OTC studies
The 86 excluded OTC studies were compared with the 
Holland, et al. [12] guidelines in terms of experimental design, 
study duration, sample size, subject selection, teeth to be included, 
test stimuli, controls, Run-in/wash-out period, subject instruction, 
outcomes, and follow up. The results are shown in Figure 2.
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Figure 2: Study compliance in the excluded studies.
Included studies
The included studies [17-51] were compared with the Holland et al. guidelines [12] in terms of experimental design, study duration, 
sample size, subject selection, teeth to be included, test stimuli, controls, Run-in/wash-out period, subject instruction, outcomes, and 
follow up. The main features and characteristics of the included studies compared to the Holland, et al. [12] guidelines are summarized 
in Table 1 and Figure 3.
Authors
Study 
design
Study 
Duration
Sam-
ple 
size
Subject 
Selection
Number 
of test/ 
control 
teeth
Test 
Stim-
uli
Adequate 
controls
Assess-
ment
Wash in/
Wash  
out 
periods
Subject 
Instruction
Out-
comes
Fol-
low 
up
RCT 
double 
blind
Mini-
mum 6 
weeks
At 
least 
25  
per 
group
Healthy 
individu-
als  
diag-
nosed 
with DH
At least 2 
teeth
At 
least 2
Negative 
or  
minus 
active
Stimu-
lus 
based 
or  
re-
sponse 
based  
or sub-
jective 
evalua-
tion
Speci-
fied 
period
Partici-
pant  
instruc-
tion sheet
Re-
duc-
tion  
in pain
(Ces-
sation 
of 
treat-
ment)
Schiff, et al. 
[17] Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes No
Yates, et al. 
1998. [18] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
Kaufmann, et 
al. [19] Yes Yes Yes Yes
No (not 
men-
tioned)
Yes Yes Yes No Yes Yes No
Schiff, et al. 
[20] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Schiff, et al. 
[21] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Sowiniski, et 
al. [22] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Sowiniski, et 
al. [23] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
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Pereira & 
Chava [24] Yes Yes Yes Yes
No (not 
men-
tioned)
Yes Yes Yes No Yes Yes No
Sowiniski, et 
al. [25] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Schiff, et al. 
[26]
Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Wara-aswapati 
et al. [27] Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes No
Yates, et al. 
[28] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Schiff, et al. 
[29] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Du Min, et al. 
[30] Yes No Yes Yes Yes Yes Yes Yes No Yes Yes No
Ghassemi, et 
al. [31] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Litkowski & 
Greenspan [32] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Pradeep and 
Sharma [33] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Que, et al. [34] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Chaknis, et al. 
[35] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Kakar, et al. 
[36]
Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Pradeep, et al. 
[37] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Elias-Bonata, 
et al. [38] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Hegde, et al. 
[39] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Hu, et al. [40] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Kakar, et al. 
2013 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Kakar, et al 
2013 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Kumari et al. 
[43] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Parkinson, et 
al. [44] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
He, et al. [45] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
Naoum, et al. 
[46]
Yes No Yes Yes Yes Yes Yes Yes No Yes Yes Yes
Parkinson, et 
al. [47] Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No
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Hong, et al. 
[48] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No
Parkinson, et 
al. [49] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
Sufi, et al. [50] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
Sufi, et al. [51] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
Table 1: The main features and characteristics of the included studies compared with the Holland, et al. [12] guidelines.
Figure 3: Study compliance in the included studies compared to the Holland, et al. [12] guidelines.
Analysis of the included studies
Study design
All the included studies followed the recommended  study 
design guidelines Holland et al. [12] (Figure 3). According to 
Schulz [16], random allocation to intervention groups in a clinical 
study appears to be the only method of ensuring that the groups 
being compared have an equivalent foothold at study outset hence 
eliminating confounding factors or the introduction of bias into the 
study. The success of randomization depends on:
a) Generating a system or sequence by which study subjects 
have equal possibilities of being allocated to the different 
intervention groups and. 
b) Allocation concealment such as blinding or masking which 
reduces the introduction of bias, confounding factors by 
shielding the intervention received by each specific group.
All the studies randomized their participants to the various 
test and control groups although it was unclear in some of the 
studies as to how they completed the randomization and allocation 
process. It was clear from most of the included studies that they 
were either sponsored by an Oral Health Care Company or 
followed a protocol based on their recommendations and as such 
the randomization and allocation of interventions to the various 
treatment groups would be based on a randomized code to blind 
either the study staff or subject (single blind) or both the staff/subject 
(double-blind). For example randomization based on stratification 
according to the participants’ age, gender, baseline mean thermal 
(air blast) and tactile (Yeaple Probe) sensitivity scores in to the 
treatment groups or a modification of these variables 17, 20, 21,22, 
23, 25, 26, 28, 40, 47. Other studies used a randomisation process 
involving a lottery method to allocate participants to the various 
groups [33], or used a computer-generated random table to ensure 
double blinding during the study [37] as well as using a list of 
random numbers sequentially from a Sponsor’s Biostatistics Unit 
[38,43-45,49-51]. The study by Naoum, et al. [46] used a computer 
algorithm to limit the impact of age, gender, diet, and current level 
of oral hygiene on the study. The methodology used to maintain 
blinding during the study was not always clearly described in 
the studies, but it would be normal practice to overwrap the test 
and control dentifrices or have similar tubes/mouth rinses with 
labels with the assigned code (allocation concealment or masking) 
[18,33,37,38,43,50,51].
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Duration
All the included studies meet the guidelines in relation to the 
study duration ranging from six to 12 weeks (assessment at baseline, 
mid-point, end-point assessment). There were five studies of six 
weeks duration [24,30,33,36,48], one study of 10 weeks duration 
[46] two studies over 12 weeks duration [27,43] and 27 of studies 
of eight weeks duration [17-23,25-26,28,29,31,32,34,35,37-
42,44,45,47,49-51].
Sample Size and Statistical Power
33466 participants were enrolled in the included studies 
and included both male and female participants with an age range 
from 18-70 years. Most of the included studies (91%; n=32) 
included at least 25 subject per arm, three studies [17,32,46], 
included less than 25 per arm. Only 12 studies provided 
information on any power calculation (formally or informally), 
for example to detect statistically significant differences between 
treatment  groups using a two tailed alpha 0.05 and a power of 
80% [30-33,36,39,44- 45,47,49-51]. Studies also included a 5% 
or 10% ‘drop out’ calculation to allow for the relevant number 
of participants completing the respective studies. The rest of the 
studies in this review did not appear to report any details on sample 
size calculation.
Consideration of Withdrawals and Dropouts
Any withdrawals and dropouts that occur following the 
randomization process may affect the balance of the groups 
established via the randomization procedure. One way of avoiding 
this problem is by reporting on the number of withdrawals or 
dropouts as if they were still a part of the clinical trial; this is called 
the intention-to-treat analysis (52). The number of ‘drop-outs’ was 
reported in most of the included studies although only few studies 
included ITT analysis [18,31,40,44,47,49,51].
Subject Selection
AAll included studies broadly complied with the Holland, et 
al. [12] guidelines regarding the inclusion/exclusion criteria of the 
study populations by including participants with a known history 
of DH, assessment and at least two stimuli etc. Participants with 
existing medical conditions, allergies to the product ingredients, 
dental status that would preclude testing (periodontal condition, 
crowns, abutment teeth, carious teeth) pain medication that would 
conflict with the pain assessment and female participants who were 
pregnant or nursing mothers were excluded from participating in 
the studies. Participants who were unwilling or unable to provide 
written consent or unable to complete the proposed study were 
also excluded.
Run In /Wash-Out Period and Follow Up Assessments
Only eight (22.8%) of the studies included a pre-trial 
run-in/wash-out period ranging from seven days to six weeks 
[17,18,27,31,48-51]. A further two studies reported on a follow 
up period following the cessation of the intervention [31,46] 
with Ghasssemi, et al. [31] switching the participants from the 
Enamel Care group after eight weeks to the control dentifrice for a 
further eight weeks to determine the degree of persistence of pain 
reduction. Naoum, et al. [46] reported on a four-week follow-up 
period following the cessation of active treatment.
Subject Instruction
 All the included studies complied with the guidelines in 
this aspect (Table 1). Generally speaking all the studies included 
information on whether the participants provided their consent 
following their reading of the relevant paperwork, these instructions 
were also verbally reinforced during the study in relation to the 
number of daily brushing, exclusion of other oral hygiene aids and 
dental products. Most studies indicated a twice daily brushing with 
the assigned dentifrice although some studies did not specify for 
how long, but the assumption would be one minute twice daily 
[17-26,28-45,47-51]. The exception to the one-minute brushing 
regime was the studies by Wara-aswapati, et al. [27] and Naoum, 
et al. [46] where the participants were asked to brush twice daily 
for two minutes. There were five mouthwash studies where the 
participants were asked to brush their teeth for one-minute with 
or without a toothpaste prior to rinsing with their allocated 
mouthwash for one-minute (twice daily) [18,24,38,40,48].
DH Stimulus and Assessment
All included studies included at least two test stimuli, with 
the exception of Ghassemi, et al. [31] who only used an air-blast 
stimulus (thermal)(VAS and Schiff Scale). Most studies used the 
Yeaple probe as the main assessment of tactile stimulation [17-
18,20-26,29,32,34-36,38-42,44,45,47,49,50,51] as well as an air 
blast. Other studies used alternative tactile stimuli for example a 
Jay probe [39,41,42], a Scratchometer [19] or an electrical stimulus 
(Sensitometer) [19] or a dental explorer probe or equivalent (e.g. 
periodontal probe) with an air blast [27,28,30,31,33,37,43,48]. 
Naoum, et al. [46] used a combination of tactile (explorer 
probe), air blast and a 70% hypertonic sucrose solution. 
Eight (22.8%) of the included studies (included a subjective 
evaluation of the participants’ overall sensitivity to everyday 
stimuli [19,24,34,39,41,42,50,51]. Only two studies included 
an assessment of the impact of DH treatment on the Quality of 
Life. (QoL) of the participants using a Dentine Hypersensitivity 
Experience Questionnaire (DHEQ) [50-51], although Parkinson, 
et al. [44] included it in the methodology but may not have report 
the findings. Historically an air blast from a dental air syringe was 
used to assess the evaporative or thermal response for DH with the 
participants either using a VAS [19,24,27-28,30-31,33,37,39,41-
43,47-49] or VRS [18,50-51] to indicate the level of discomfort. 
The second most common approach was the Schiff scale to 
measure air blast stimuli. 23 of the included studies now favor 
using the 0-3 Schiff Scale (0-3) [17,20-26,29,31-32,34-36,38-
40,44-47,49-51]. Several investigators used a variety of stimuli to 
assess the thermal response such as an ice stick [48] or 5/10ml of 
ice-cold water [28,33,37,43].
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Interventions
There were a variety of different test interventions and 
control dentifrice and mouthwash products but generally speaking 
a placebo/negative control was either a fluoride (Sodium fluoride 
[NaF] [19,21,23,25,26,29,35,45,49], Monofluorophosphate 1000 
ppm Fluoride [MFP][17,27,34,36,39,41,42,44,46,47,49], Amine 
fluoride dentifrice [37] or a positive control dentifrice (a recognized 
desensitizing dentifrice) [21-23,30,33,37,49]. Other studies 
included an arm that was either minus active [30,32-34,43,50,51] 
or evaluating changes in 1) abrasive system [20] or 2) including 
an anti-plaque ingredient [27,28]. The test dentifrices were as 
follows: 1) Potassium Nitrate (KNO3) [17,20-25,27,37,41,49], 
2) Stannous Fluoride (Sn2F) [26,29,35,44,45,47], 3) 5% Calcium 
sodium-phospho-silicate (CSP) [30,32,33,37,50,51], 4) Arginine 
[34,36,39,42], 5) Potassium citrate (K3C6H5O7) [28], 6) Herbal 
(includes KNO3), 7) other miscellaneous dentifrices: Enamelon 
[19], and functionalised tricalcium phosphate (fTCP) [46], ACP 
[31] and a dentifrice containing 0.3% triclosan, 2.0% polyvinyl 
methyl ether maleic acid (PVM/MA) copolymer, 0.243% NaF 
[35]. There were five mouthwash interventions [18,24,38,40,48] 
containing the active ingredients such as 1) KNO3 [24,38,48], 2) 
K3C6H5O7  [18]  or 0.8% arginine [38,40] in either cetylpyridinium 
chloride (CPC) [18,48] or an alcohol-free base [24?, 38, 40] The 
control mouthwashes were either 1) minus-active [18,40,48] or 2) 
0.2% or 0.05% NaF [24,38]. 
Data Analysis
Data analysis was performed in all the included studies 
which included summary statistics from the baseline to the 
end-point of the study together with a variety of statistical tests 
(significance level p≤0.05) used for the various assessment 
outcomes to determine any differences between the test and control 
groups. For example, the following main statistical tests were 
used in the included studies; 1) Analysis of Variance (ANOVA) 
[17-23,25-33,43,45-47], 2) Analysis of Covariance (ANCOVA) 
[26,29,31,33-42,44-47,49-51,18-23] 3) Multiple Analysis of 
Covariance (MANCOVA) [24], 4) Combined Modality Sensitivity 
(CMS)[46], 5) paired t-tests [19,25,28,31,34,37,39,41-43,48,], 
6), Wilcoxon signed rank tests, [31,48,50,51] 7) Chi-Squared test 
[19,31], 8) Post hoc analysis (e.g., Tukey, Bonferroni correction, 
Duncan multiple range test) [27,30,33,38,43,46,48,50,51], and 9) 
Logit transformed analysis which was based on, the net number of 
sensitive teeth becoming non-sensitive together with the change 
in the proportion of sensitive teeth over the duration of the study 
[19].
Outcomes
All the authors reported on the outcomes from the included 
studies in terms of a reduction in the pain response using the various 
assessment methodology compared to the baseline values as well as 
a comparison of the between treatment difference(s) to the control 
groups [17-51]. Although there were statistical differences from 
baseline to the completion of the study in both the test and control 
groups (p ≤ 0.05) not all studies shown a statistical difference 
between the test and control groups. For example, some studies 
reported statistical differences between the test and control groups 
[17,20-23,25,26,29,31,33,35,36,38-47,50,51], whereas in other 
studies there appeared to be no significant differences despite the 
emergence of a positive trend [18,19,24,27,28,30,32,34,37]. There 
was also a statistical reduction in the pain response in the control 
groups as well as in the test. Only eight studies included the effects 
of the treatment to everyday life-stimuli [19,24,34,39,41,42,50,51], 
and only two studies reported the effects of the treatment on the 
quality of life (DHEQ)[50-51], although a study by Parkinson, 
et al. [44] included the DHEQ in the methodology but may not 
have report the findings. None of the included studies reported 
the complete absence of the pain response following any of the 
interventions at the end of the studies.
Discussion
One of the problems in evaluating DH in the clinical 
environment is the highly subjective nature of DH affecting the 
QoL which may also complicate the evaluation of the participant’s 
response to the assessment methodology when diagnosing DH in a 
dental practice or during a clinical study to evaluate the efficacy of 
a desensitizing products [3,53]. Pain is the major outcome arising 
from DH and the degree of discomfort expressed by a participant 
may depend on the individual’s pain perception and pain tolerance, 
as well as his/her emotional and physical factors. According to 
Curro and Gillam [13] there are several problems such as the 
effects of Hawthorne and placebo effects which makes it difficult 
to objectively assess the level of pain during a clinical study. 
Both these effects can have an impact on the results 
from the study. For example, simply being in a study with a 
continually reinforcement of the recommendations will improve 
the participant’s oral hygiene and  subsequently  introduces  a 
degree  of  bias  into  the  study (Hawthorne effect). The placebo 
effect where the participants report an improvement even though 
they may be in a placebo group with no active ingredient in the 
dentifrice may also give an improvement throughout the study 
(varies from 20 to 60% in DH clinical studies) [54]. The entry 
criteria for DH studies should however be reasonable and realistic 
otherwise the investigator will struggle to recruit adequate numbers 
within the allocated time frame for completion of the study. 
Care should also be taken when screening subjects not to recruit 
subjects who report either minimal or extreme discomfort as the 
statistical probability of measuring the pain response can only stay 
the same, worsen, or improve, respectively. This phenomenon is 
called regression towards the mean or mode and can magnify a 
product’s treatment effect if used on a severely affected population 
or reduce the effect when used in an under-affected population 
[11,13]. The importance of conducting well-designed RCTs has 
been emphasized by several clinical investigators [12,13,54] and 
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it was evident that prior to the publication of the Holland et al 
guidelines in 1997 [12], the standard of conducting and reporting 
DH studies was inconsistent and it should be recognized that 
since 1997 there has been an marked improvement in the conduct 
and reporting of these studies. The current review examined 
the available published literature to compare the clinical trial 
methodology used to evaluate the products for DH based on the 
inclusion criteria of the guidelines recommended by Holland, et 
al. [12]. The purpose of the review was not to evaluate the efficacy 
of these products per se but to determine whether these studies 
complied with the Holland, et al. [12] guidelines and whether 
there were any recommendations to be made in the light of the 
outcomes from the review. A total of 35 studies were included in 
this review, from an initial search of 882 titles. All included studies 
complied with the guidelines in terms of study design, duration, 
subject selection, adequate controls, and subject instruction(s). 
Those studies that were excluded from the review failed to satisfy 
the Holland, et al. [12] guidelines (Figure 2) in comparison to 
those studies that were included in the present review (Figure 3). 
There were a variety of different test interventions and control 
dentifrice and mouthwash products but generally speaking a 
placebo/negative control was either a fluoride (Sodium fluoride 
[NaF] [19,21,23,25,26,29,35,45,49], Monofluorophosphate 
1000 ppm Fluoride [MFP] [17,27,34,36,39,41,42,44,46,47,49], 
Amine fluoride dentifrice [37] or a positive control dentifrice (a 
recognized desensitizing dentifrice)[21-23,30,33,37,49]. Other 
studies included an arm that was either minus active [30,32-
34,43,50,51] or evaluating changes in 1) abrasive system [20] or 2) 
including an anti-plaque ingredient [27-28]. It should be noted that 
most studies were Company sponsored as it is very difficult to run 
an independent DH RCT due to the cost of running these studies. It 
should be noted that some of the dentifrices reported in the present 
review are no longer commercially available in the formulations 
described in the studies (e.g., 19,20-23,32). The methodology 
used for the assessment of DH in the included studies has been 
established in several review papers [12,53-55] such as the Yeaple 
probe [17,18,20-26,29,32,34-36,38-42,44,45,47,49-51], Jay 
probe [39,41,42], Scratchometer [19] or dental explorer probe or 
equivalent (e.g. periodontal probe) [27,28,30,31,33,37,43,48] for 
tactile stimulation. Only one study used an electrical stimulus an 
electrical stimulus (Sensitometer) [19]. The tactile stimulus would 
be generally used prior to the cold air blast from a dental air syringe 
or other stimuli such as cold water and hypertonic solutions. The 
rationale for this methodology is based on using the least damaging 
stimulus first as the evaporative/thermal stimulus may have a more 
lasting effect on the pain response than the tactile stimulus [53,55]. 
There does not appear to be an accepted time interval between 
each of these stimuli although five to ten minutes between each 
stimulus has been suggested [53]. Prior to any evaluation both 
the Yeaple and Jay probes should be calibrated daily by the study 
examiners, these probes register a constant force (gm) starting 
from a lower range ascending to 50-100 gm depending on the 
probe type. Following the application on the test tooth the value is 
recorded and the participant asked to complete a VAS score. The 
assessment of the air blast from a dental air syringe is also assessed 
with a VAS score but more recently this assessment is by the Schiff 
air scale (0-3) score. It could be argued that these stimuli (tactile 
and thermal) are not realistic of daily living and that more realistic 
assessment should be included in the evaluation. The use of the 
DHEQ and other QoL tools may therefore have a more important 
role in future studies. Details of calibration and training of the 
examiners were however not routinely reported in the included 
studies and this may be an area which could be improved on in 
future studies. Holland, et al. [12] Overall these studies followed 
the guidelines although there were minor variations with 1) the 
number of test stimuli used in these studies (97% compliant), 
2) minimum teeth included for assessment (91% compliant) 
and 3) sample size (91% compliant). The two areas where the 
compliance with the guidelines was poor was in 1) run in/wash 
out periods (22.8% compliant) and 2) a follow-up period after the 
cessation of the active intervention to determine the duration of 
a product’s efficacy (5.7% compliant) (Table 1). All the included 
studies reported on the effect of the intervention as a percentage 
reduction from baseline for each of the clinical parameters (tactile, 
thermal, overall sensitivity). However, while it was evident that 
there was an improvement in the various outcomes from baseline 
in both the test and control groups, none of the included studies 
reported a total relief of pain from DH. According to Holland, et 
al. [12] the main objective of a study evaluating the efficacy of 
a desensitizing dentifrice or mouthwash should be to produce a 
clinically significant reduction in symptoms rather than a small 
but statistically significant reduction between the intervention and 
its control. One of the problems however in evaluating the efficacy 
of the various interventions in the present review was that both 
test and control groups in each of the included studies reported a 
significant statistical reduction of pain from baseline which would 
suggest that both placebo and non-placebo (Hawthorne) effects 
confounded the results reported in these studies.
One of major findings from the present review was that 
there was a lack of compliance with two of the recommendations 
from Holland et al. [12] namely 1) a run-in/wash out period and 
2) an evaluation of the effects of DH on the participants’ QoL. 
Only eight (22.8%) of the included studies mentioned a pre-trial 
run-in/wash-out period ranging from seven days to six weeks 
[17-18,27,31,48-51]. A further two studies reported on a follow 
up period following the cessation of the intervention [31,46] 
with Ghasssemi et al. [31] switching the participants from the 
Enamel Care group after eight weeks to the control dentifrice for a 
further eight weeks to determine the degree of persistence of pain 
reduction. Naoum, et al. [46] reported on a four-week follow-up 
period following the cessation of active treatment. The advantage 
of including a run in/wash out period before the commencement of 
a study is that it allows for any potential therapeutic benefits from 
the participants’ previous desensitizing toothpaste to be minimized 
since the participants will be on a standardize brushing regime with 
a fluoride dentifrice and standardized toothbrushes. As observed 
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from the present review there was a range of recommended wash 
in/wash out periods from seven days to six weeks however there 
does not appear to be any information as to an ideal duration for 
a run-in/wash period [12]. The inclusion of a period following the 
cessation of the intervention [31,46] may also be of importance as 
it determine the duration of a desensitizing dentifrice’s efficacy. 
This observation if standardized from several studies may provide 
a basis for recommending the minimum duration of a run in/wash 
out period to nullify any carry-over effects from the previous 
dentifrice used by the participants. According to Gillam [11] the 
disadvantage of including a longer run in/wash out period would be 
to increase the duration and cost of running DH studies. Holland, 
et al. [12] also recommended in the guidelines that studies should 
impact of the various interventions on the participants’ daily 
activities (Subjective response) as well as the impact on their 
QoL. Only eight studies appeared to include the effects of the 
interventions to everyday life-stimuli [19,24,34,39,41-42,50-51] 
and only two studies reported the effects of the intervention on 
the QoL (DHEQ)[50-51] although a study by Parkinson, et al. [44] 
included the DHEQ in the methodology but may not have report 
the findings. According to Bekes and Hirsch [4] QoL research 
has gained increasing recognition in both Medicine and Dentistry 
and while this approach was previously regarded as a secondary 
outcome to complement biological and clinical markers of disease 
and as such should be included in any future recommendations for 
running DH studies. 
 Conclusions
All of the included studies reported a significant statistical 
reduction of pain in both the test and control groups, although 
none of the studies reported the complete absence of the pain 
response following any of the interventions at the end of the 
studies. Overall, most studies complied with the recommendations 
from the Holland, et al., guidelines [12] however, there is still a 
need to include both a run in/wash out and follow up periods in 
future studies. Furthermore, it may be recommended to include a 
subjective evaluation of the treatment outcome to overall sensitivity 
from day to day activities as well as the effect on the QoL (person-
centered approach) in future studies. None of the included studies 
reported the complete absence of the pain response following any 
of the interventions at the end of the studies. 
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